The Business Research Company’s report on the RNA Targeting Small Molecules Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the rna targeting small molecules therapeutics market in recent years?
The increasing number of cancer cases is expected to propel the growth of the RNA-targeting small molecule therapeutics market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer is treated with RNA-targeting small molecules created and investigated to target RNA molecules associated with cancer selectively. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. It is about 1,670 fatalities each day. Therefore, the increasing number of cancer cases is driving the growth of the RNA-targeting small molecule therapeutics market.
Access Your Free Sample of the Global RNA Targeting Small Molecules Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp
What is the projected market size of the rna targeting small molecules therapeutics industry, and how is it expected to grow?
The RNA targeting small molecules therapeutics market size has grown exponentially in recent years. It will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. The growth in the historic period can be attributed to drug discovery and development, rising prevalence of RNA-related diseases, government and private funding, pharmaceutical industry interest, RNA therapeutics success stories
The RNA targeting small molecules therapeutics market size is expected to see exponential growth in the next few years. It will grow to $22.36 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, rise in RNA biomarker identification, expanding RNA target spectrum, increasing funding and investments, application in rare diseases. Major trends in the forecast period include advancements in screening technologies, antisense oligonucleotides dominance, small molecule RNA binders, RNA therapeutics in neurological disorders, gene editing with crispr-cas9.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp
Who are the key players driving competition in the rna targeting small molecules therapeutics market?
Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics
What key trends are expected to drive the rna targeting small molecule drug discovery market during the forecast period?
Strategic partnerships are a key trend gaining popularity in the RNA-targeting small molecule therapeutics market. Major companies operating in the RNA-targeting small molecule therapeutics market are undergoing partnerships to develop a new relationship in which two or more organizations develop innovative products. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing company, collaborated with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. With this partnership, xFOREST will offer Otsuka with its Forest technology to advance systemic small-molecule drug discovery research focusing on RNA structures. Furthermore, in April 2024, Ipsen, a France-based biopharmaceutical company partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that provides RNA-targeting small molecule therapeutics. With this collaboration, Ipsen aimed at developing RNA-targeting small molecule drugs for rare neurological diseases and integrates various data sets to identify and develop small molecules that can modulate RNA.
Which key geographies are driving the growth of the rna targeting small molecules therapeutics market?
North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
What are the key segments driving growth in the rna targeting small molecules therapeutics market?
The RNA targeting small molecules therapeutics market covered in this report is segmented –
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation
2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides
3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers
4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253
What defines the structure and scope of the rna targeting small molecules therapeutics market?
RNA-targeting small molecule therapeutics refers to small molecule therapeutics that precisely interact with RNA molecules to modify their function or stability. These treatments treat diseases by employing small-molecule drugs to target disease-causing RNA molecules.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
